Watch BIXT. Know when insiders buy.
One email the day a filing lands. Free.
BIXT
BIOXYTRAN, INC
0.02
+0.00 +3.86%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $2.4MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$3.5MNET CASH —52W 0.02 – 0.09SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$655K | −$620K | −1849.3% | -0.01 | −$350K | — | — | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$1.9M | −$2.1M | — | -0.02 | −$239K | — | — | Aug 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$607K | −$522K | — | 0.00 | −$237K | — | — | Apr 15 |
| Q3 2025 · Sep 30 | — | — | — | −$496K | −$283K | — | 0.00 | −$49K | — | — | Nov 14 |
| Q2 2025 · Jun 30 | — | — | — | −$224K | $35K | — | 0.00 | −$73K | — | — | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$515K | −$1.4M | — | -0.02 | −$167K | — | — | Aug 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$488K | −$752K | — | -0.01 | −$128K | — | — | Apr 15 |
| Q3 2024 · Sep 30 | — | — | — | −$346K | −$392K | — | 0.00 | −$74K | — | — | Nov 14 |
| Q2 2024 · Jun 30 | — | — | — | −$609K | −$662K | — | 0.00 | −$70K | — | — | Nov 14 |
| Q1 2024 · Mar 31 | — | — | — | −$779K | −$561K | — | 0.00 | −$110K | — | — | Nov 14 |
| Q4 2023 · Dec 31derived | — | — | — | −$1M | −$1.1M | — | 0.00 | −$93K | — | — | Apr 3 |
| Q3 2023 · Sep 30 | — | — | — | −$985K | −$1.1M | — | -0.01 | −$343K | — | — | Oct 29 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$1.8M | −$2.1M | — | -0.02 | −$526K | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$2.2M | −$2.4M | — | -0.02 | −$381K | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$3.8M | −$4.5M | — | -0.03 | −$775K | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$2.4M | −$2.5M | — | -0.02 | −$1.8M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$4.2M | −$4M | — | -0.04 | −$1.7M | — | — | — | — |
| FY2020 · to Dec 31 | — | — | −$1.3M | −$2.5M | — | -0.03 | −$1.1M | — | — | — | — |
Every number comes from BIOXYTRAN, INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.